Connect Biopharma Holdings (CNTB) Common Equity (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Common Equity for 7 consecutive years, with $42.6 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity fell 48.58% year-over-year to $42.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.6 million (down 48.58% YoY) and the FY2025 annual result came in at $42.0 million, down 54.45% from the prior year.
• Common Equity climbed to $42.6 million in Q1 2026 per CNTB's latest filing, from $42.0 million in the prior quarter.
• Over the last five years, Common Equity for CNTB reached as high as $213.0 million in Q2 2022 and fell as low as $42.0 million in Q4 2025.
• A 5-year average of $99.2 million and a median of $93.9 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity dropped 9.19% — and 2025, when it sank 54.45%.
• Year by year, Common Equity stood at $154.2 million in 2022, then sank by 34.19% to $101.5 million in 2023, then slipped by 9.19% to $92.2 million in 2024, then sank by 54.45% to $42.0 million in 2025, then advanced by 1.53% to $42.6 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $42.6 million, $42.0 million, and $55.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.